Patrizia Popoli

Dr. Patrizia Popoli

Auto-generated profile, based on publicly available information

Dr. Patrizia Popoli


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2002 in Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
PPPatrizia Popoli
Patrizia Popoli
APAnnita Pintor
Annita Pintor
MDMaria Rosaria Domenici
Maria Rosaria Domenici
CFClaudio Frank
Claudio Frank
MTMaria Teresa Tebano
Maria Teresa Tebano
MMMarino Massotti
Marino Massotti
The aim of the present study was to evaluate whether, and by means of which mechanisms, the adenosine A2A receptor antagonist SCH 58261 [5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine] exerted neuroprotective effects in a rat model of Huntington9s disease. In a first set of experiments, SCH 58261 (0.01 and 1 mg/kg) was administered intraperitoneally to Wistar rats 20 min before the bilateral striatal injection of quinolinic acid (QA) (300 nmol/1 μl). SCH 58261 (0.01 but not 1 mg/kg, i.p.) did reduce significantly the effects of QA on motor activity, electroencephalographic changes, and striatal gliosis. Because QA acts by both increasing glutamate outflow and directly stimulating NMDA receptors, a second set of experiments was performed to evaluate whether SCH 58261 acted by preventing the presynaptic and/or the postsynaptic effects of QA. In microdialysis experiments in naı̈ve rats, striatal perfusion with QA (5 mm) enhanced glutamate levels by ∼500%. Such an effect of QA was completely antagonized by pretreatment with SCH 58261 (0.01 but not 1 mg/kg, i.p.). In primary striatal cultures, bath application of QA (900 μm) significantly increased intracellular calcium levels, an effect prevented by the NMDA receptor antagonist MK-801 [(+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate]. In this model, bath application of SCH 58261 (15–200 nm) tended to potentiate QA-induced calcium increase. We conclude the following: (1) the adenosine A2A receptor antagonist SCH 58261 has neuroprotective effects, although only at low doses, in an excitotoxic rat model of HD, and (2) the inhibition of QA-evoked glutamate outflow seems to be the major mechanism underlying the neuroprotective effects of SCH 58261.


12 September 2005 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
MTM. T. Tebano
M. T. Tebano
AMAlberto Martire
Alberto Martire
NRN. Rebola
N. Rebola
RPR. Pepponi
R. Pepponi
MDM. R. Domenici
M. R. Domenici
PPP. Popoli
P. Popoli

30 April 2007 in Progress in Neurobiology
Verified
Journal Article
Closed access
PPPatrizia Popoli
Patrizia Popoli
DBDavid Blum
David Blum
AMAlberto Martire
Alberto Martire
CLCatherine Ledent
Catherine Ledent
SCStefania Ceruti
Stefania Ceruti
MAMaria Abbracchio
Maria Abbracchio

9 December 2003 in Neurology
Verified
Journal Article
Closed access
PPP. Popoli
P. Popoli
CFC. Frank
C. Frank
MTM.T. Tebano
M.T. Tebano
RPR.L. Potenza
R.L. Potenza
APA. Pintor
A. Pintor
APA. Pèzzola
A. Pèzzola
Because an increased glutamate outflow is thought to play a crucial role in triggering excitotoxic neuronal death, drugs able to regulate glutamate release could be effective for the management of neurodegenerative diseases. In this article, the authors discuss the hypothesis that adenosine A2A receptor antagonists (A2A antagonists) may belong to the aforementioned category. In rats bilaterally lesioned with the excitotoxin quinolinic acid (QA) in the striatum, the A2A antagonist SCH 58261 significantly reduced the motor, EEG, and neuropathologic changes induced by the lesion. Such effects of SCH 58261 occurred only at low doses and were paralleled by an inhibition of QA-stimulated glutamate release. The role played by A2A antagonists in the regulation of glutamate outflow was also confirmed by preliminary results obtained in the model of paired-pulse stimulation in corticostriatal slices. Conversely, based on data obtained in cultured striatal neurons, A2A antagonists appear unable to directly inhibit NMDA effects. In conclusion, A2A antagonists show clear neuroprotective effects in models of brain injury, although their actual therapeutic potential needs to be confirmed in a wider range of doses and in models of neurodegenerative diseases in which presynaptic and postsynaptic effects play different relative roles.

2 December 2010 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
AMAlberto Martire
Alberto Martire
MTMaria Teresa Tebano
Maria Teresa Tebano
VCValentina Valentina Chiodi
Valentina Valentina Chiodi
SFSamira Ferreira
Samira Ferreira
Rodrigo CunhaRodrigo Cunha
Rodrigo Cunha
PPPatrizia Popoli
Patrizia Popoli